000121081 001__ 121081 000121081 005__ 20230111133135.0 000121081 0247_ $$2doi$$a10.3390/ECMC2022-13227 000121081 0248_ $$2sideral$$a131748 000121081 037__ $$aART-2022-131748 000121081 041__ $$aeng 000121081 100__ $$aFresquet Molina, Raquel 000121081 245__ $$aComparative Clinical Efficacy Study between Erenumab and Fremanezumab 000121081 260__ $$c2022 000121081 5060_ $$aAccess copy available to the general public$$fUnrestricted 000121081 5203_ $$aA retrospective comparative study was conducted to compare the efficacy of monoclonal antibody drugs against the calcitonin gene-related peptide pathway in migraine and to establish whether they can be considered equivalent therapeutic alternatives for this pathology. A total of 21 patients with chronic migraine were treated with Fremanezumab 225 mg/30 days and 24 patients treated with Erenumab 70 mg/30 days for at least 6 months. Data were collected at baseline and at six months using the following scales: Headache Impact Test (HIT), Migraine Disability Assessment Scale (MIDAS), and a numerical scale of pain intensity (0 (no pain) and 10 (unbearable pain)). Days of migraine per month were recorded. Mean HIT at baseline and 6 months for Fremanezumab and Erenumab was 68.6 (62–76) and 54 (36–70) and 66 (42–78) and 53 (9–72), respectively. In both cases, it decreased by more than 6 points (efficacy criteria). Mean MIDAS at baseline and 6 months for Fremanezumab and Erenumab was 70 (25–127) and 25 (0–135) and 73.3 (19–150) and 23 (0–68), respectively. In both cases, it decreased by more than 30% (efficacy criteria). Mean pain intensity at baseline and 6 months for Fremanezumab and Erenumab was 8.8 (6–10) and 6(5–8) and 8.6 (7–10) and 6 (10–0), respectively. Mean number of migraine days in a month at baseline and 6 months for Fremanezumab and Erenumab were 16.6 (10–30) and 5.3 (0–11) days and 17 (3–30) and 5.8(–15) days, respectively. In both cases, the reduction was > 50%. It can be concluded that the initial values of the scales are very similar. The initial situation of the patient is not a trigger for the use of one drug or the other. Clinically, there is no difference between the two drugs. 000121081 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/ 000121081 655_4 $$ainfo:eu-repo/semantics/conferenceObject$$vinfo:eu-repo/semantics/publishedVersion 000121081 700__ $$0(orcid)0000-0001-9962-3387$$aSopena Carrera, Lucía$$uUniversidad de Zaragoza 000121081 700__ $$aVinuesa Hernando, José Manuel 000121081 700__ $$aMerchán Flores, Aritz 000121081 700__ $$aCazorla Poderoso, Lucía 000121081 700__ $$aPérez Moreno, María 000121081 700__ $$aFrutos Pérez-Surio, Alberto 000121081 700__ $$aArenere Mendoza, Mercedes 000121081 700__ $$aPardo Jario, María del Puerto 000121081 700__ $$aAllende Bandrés, María de los Ángeles 000121081 700__ $$aSalvador Gómez, Tránsito 000121081 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ. 000121081 773__ $$g14, 1 (2022), 54 [1 pp]$$pMed. sci. forum$$tMedical sciences forum$$x2673-9992 000121081 8564_ $$s206914$$uhttps://zaguan.unizar.es/record/121081/files/texto_completo.pdf$$yVersión publicada 000121081 8564_ $$s2477673$$uhttps://zaguan.unizar.es/record/121081/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000121081 909CO $$ooai:zaguan.unizar.es:121081$$particulos$$pdriver 000121081 951__ $$a2023-01-11-08:44:36 000121081 980__ $$aARTICLE